SB-366791, TRPV1 antagonist (ab141772)
Key features and details
- Potent, selective TRPV1 antagonist
- CAS Number: 472981-92-3
- Purity: > 99%
- Soluble in DMSO to 75 mM and in ethanol to 25 mM (with warming)
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
SB-366791, TRPV1 antagonist -
Description
Potent, selective TRPV1 antagonist -
Biological description
Potent, selective TRPV1 antagonist. Rapidly and reversibley inhibits capsaicin, acid, or heat mediated activation of human TRPV1 (IC50 values are 3 and 6 nM for capsaisin and heat respectively). Active in vivo. -
Purity
> 99% -
CAS Number
472981-92-3 -
Chemical structure
Properties
-
Chemical name
(E)-3-(4-Chlorophenyl)-N-(3-methoxyphenyl)prop-2-enamide -
Molecular weight
287.80 -
Molecular formula
C16H14CINO2 -
PubChem identifier
667594 -
Storage instructions
Store at Room Temperature. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 75 mM and in ethanol to 25 mM (with warming) -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
COC1=CC=CC(=C1)NC(=O)C=CC2=CC=C(C=C2)Cl -
Source
Synthetic
-
Research areas
Images
-
Chemical Structure - SB-366791, TRPV1 antagonist (ab141772)2D chemical structure image of ab141772, SB-366791, TRPV1 antagonist
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab141772 has been referenced in 3 publications.
- Shalev N et al. Phytocannabinoid Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian Cancer Cells In Vitro and Affect the Wnt Signaling Pathway. Molecules 27:N/A (2022). PubMed: 36364346
- Anis O et al. Cannabis-Derived Compounds Cannabichromene and ?9-Tetrahydrocannabinol Interact and Exhibit Cytotoxic Activity against Urothelial Cell Carcinoma Correlated with Inhibition of Cell Migration and Cytoskeleton Organization. Molecules 26:N/A (2021). PubMed: 33477303
- Anil SM et al. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep 11:1462 (2021). PubMed: 33446817